Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,849 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Stewart AK, et al. Among authors: xing b. N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6. N Engl J Med. 2015. PMID: 25482145 Free article. Clinical Trial.
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Stewart AK, et al. Among authors: xing b. J Clin Oncol. 2016 Nov 10;34(32):3921-3930. doi: 10.1200/JCO.2016.66.9648. J Clin Oncol. 2016. PMID: 27601539 Free PMC article. Clinical Trial.
Emerging contaminants: A One Health perspective.
Wang F, Xiang L, Sze-Yin Leung K, Elsner M, Zhang Y, Guo Y, Pan B, Sun H, An T, Ying G, Brooks BW, Hou D, Helbling DE, Sun J, Qiu H, Vogel TM, Zhang W, Gao Y, Simpson MJ, Luo Y, Chang SX, Su G, Wong BM, Fu TM, Zhu D, Jobst KJ, Ge C, Coulon F, Harindintwali JD, Zeng X, Wang H, Fu Y, Wei Z, Lohmann R, Chen C, Song Y, Sanchez-Cid C, Wang Y, El-Naggar A, Yao Y, Huang Y, Cheuk-Fung Law J, Gu C, Shen H, Gao Y, Qin C, Li H, Zhang T, Corcoll N, Liu M, Alessi DS, Li H, Brandt KK, Pico Y, Gu C, Guo J, Su J, Corvini P, Ye M, Rocha-Santos T, He H, Yang Y, Tong M, Zhang W, Suanon F, Brahushi F, Wang Z, Hashsham SA, Virta M, Yuan Q, Jiang G, Tremblay LA, Bu Q, Wu J, Peijnenburg W, Topp E, Cao X, Jiang X, Zheng M, Zhang T, Luo Y, Zhu L, Li X, Barceló D, Chen J, Xing B, Amelung W, Cai Z, Naidu R, Shen Q, Pawliszyn J, Zhu YG, Schaeffer A, Rillig MC, Wu F, Yu G, Tiedje JM. Wang F, et al. Among authors: xing b. Innovation (Camb). 2024 Mar 13;5(4):100612. doi: 10.1016/j.xinn.2024.100612. eCollection 2024 Jul 1. Innovation (Camb). 2024. PMID: 38756954 Free PMC article. Review.
1,849 results